

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/560,659	Applicant: Mortlock <i>et al.</i>
Filing Date: December 13, 2005	Attorney Docket No.: 101117-1P US
Examiner: Tamthom Ngo Truong	Group Art Unit: 1624
Customer No.: 44992	Confirmation No.: 2270
Title: CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SEQUENCE LISTING STATEMENT AND REQUEST FOR ENTRY

Sir:

The following statement is in support of a computer readable form of submission under 37 C.F.R. § 1.821:

In compliance with 37 C.F.R. §1.821, the information recorded in the computer readable form is identical to the paper copy of the substitute Sequence Listing. Moreover, in accordance with 37 C.F.R. §1.821, the Sequence Listing submitted herewith does not add new matter to the application. As such, Applicant hereby requests entry into the application of the Sequence Listing submitted herewith.

Respectfully submitted,
/Jacob G. Weintraub/

Name: Jacob G. Weintraub
Dated: June 26, 2009
Reg. No.: 56,469
Phone No.: 781-839-4182
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451